SlideShare a Scribd company logo
1 of 15
Download to read offline
Editorial Slides
VP Watch – September 11, 2002 - Volume 2, Issue 36
Influence of Statin Therapy on Progression ofInfluence of Statin Therapy on Progression of
Coronary CalcificationCoronary Calcification
Matthew J. Budoff, MD, FACCMatthew J. Budoff, MD, FACC
Assistant Professor of MedicineAssistant Professor of Medicine
Division of CardiologyDivision of Cardiology
Harbor- UCLA Medical Center
Torrance, CA, USA
Coronary Calcification
Coronary Calcification has been demonstrated
to be a marker of atherosclerosis and
cardiovascular risk1
Electron Beam Tomography (EBT) is a non-
invasive method to detect and quantify
coronary calcification
Prognostic studies have demonstrated an
increased risk of future cardiac events with
increased coronary calcium scores1
Progression of AtherosclerosisProgression of Atherosclerosis
Regression studies have predominantly been
performed with angiographic trials, requiring
multiple invasive angiographic studies
These studies are typically 2-4 years in
duration, demonstrating small but significant
changes, with luminal diameter changing by
microns
It is well known that Luminal stenosis by
angiography poorly quantitates atherosclerotic
burden
EBT and ProgressionEBT and Progression
Several studies with EBT have demonstrated
progression of calcium scores of up to 50% per
year2,3,4
Variability of sequential EBT scans has been
demonstrated to range from 8-24% (mean), with
median values of 5-8%5,6
It has been demonstrated that EBT can track
progression of coronary calcium over time, and
progression of CAC has been demonstrated to be
associated with increased cardiovascular risk7,8
Progression of CAC and The
Relation to Therapy
(adapted from ref 7)
AUTHOR n KNOWN CAD? No Therapy Statin
Treatment
Type of Therapy
Janowitz 20 No
Yes
18%
27%
-------- ---------
Callister 27 No 44% -------- ---------
Callister 149 No 52%
(n = 44)
5%
(n = 105)
Statins
Maher 81 No 24% -------- ---------
Budoff 299 No 36%
(n = 239)
15%
(n = 60)
Statins
Mitchell 347 No 21% --------- ----------
Brown 160 Yes 40% 20% Simvastatin, Niacin
Achenbach 66 No 25% 8.8% Cerivastatin 0.3
mg/day
Annual Event Rate with Progression
of CAC
(Adapted from Reference 8)
0
1.5
6.45
0
1
2
3
4
5
6
7
AnnualEventRates
No progression 1-20% Increase >20% Increase
Annual CAC Score Change Shah et al, AHA 2001
Calcium Score progression with
increasing LDL Cholesterol
(Adapted from Reference 2)
+120%
0
–80%
60 120 200
LDL (mg/dL)
Treated Untreated Suboptimal Therapy (LDL >120 mg/dl)
Callister et al. N Engl J Med. 1998;339:1972-1978.
CACScoreChange
Achenbach et al, Circulation
2002
66 patients with known high cholesterol
underwent EBT scanning
Baseline calcium scores were 155 mm3
Patients were observed for a mean of 14
months
Follow-up scan revealed score increase to
201 mm3
(25%)
Treatment Arm - Cholesterol
Patients were then treated (open label) on
Cerivastatin 0.3 mg/dl for 12 months
Mean LDL was reduced from was 164 mg/dl
to 107 mg/dl (35% reduction, p<0.0001)
Mean HDL increased from 51 mg/dl to 52
mg/dl (1.7% increased, not significant)
Mean Triglycerides decreased from 184 mg/dl
to 152 mg/dl (17%, p=0.004)
EBT Changes with Statin Therapy
EBT score increased from 201 mm3
to 203
mm3
Median increase in score (on treatment was
8.8%, significantly lower than no therapy
25%, p<0.0001)
In 32 patients, on-treatment LDL cholesterol
was <100 mg/dl, median change was –3.4%
Progression of EBT by LDL
-3.4
8.8
25
-100102030
Annual
Progression
<100 Treated Untreated
TREATMENT LDL
Achenbach, Circulation 2002
P<0.001
Study Limitations
Study was stopped prematurely due to
Cerivastatin’s withdrawal from the
marketplace
Open Label study
80% triggering of EBT used (higher variability
than early diastolic trigger)
Conclusions:
Cerivastatin significantly reduced rates of
coronary calcium progression
Achieving an LDL cholesterol of <100 mg/dl
was associated with a median decrease of
the coronary calcium burden (-3.4%)
This study correlates with retrospective
studies previously published on EBT that
statin therapy will slow calcification deposition
Questions:
Does slowing of the calcification burden correlate
with slowing of the atherosclerotic plaque volume ?
Will helical (fast) CT be able to measure these
changes, given the lower reproducibility due to
slower scan times?10
Will slowing of the coronary calcium burden be
associated with a reduction in cardiovascular
events?
References
1. Budoff MJ. Prognostic Value of Coronary Artery Calcification. J Clin Out Manag 2001:8;42-48.
2. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo NJ. Effect of HMG-CoA Reductase Inhibitors on Coronary Artery Disease as
Assessed by Electron-Beam Computed Tomography. N Engl J Med 1998;339:1972-8.
3. Maher JE, Bielak LF, Raz JA, Sheedy PF, Schwartz RS, Peyser PA. Progression of coronary artery calcification: A pilot study. Mayo
Clin Proc 1999;74:347-355.
4. Budoff MJ, Lane KL, Bakhsheshi H, et al. Rates of progression of coronary calcification by electron beam computed tomography.
Am J Cardiol 2000; 86:8-11.
5. Achenbach S, Ropers D, Mohlenkamp S, et al. Variability of Repeated Coronary Artery Calcium Measurements by Electron Beam
Tomography. Am J Cardiol 2001;87:210-213.
6. Mao SS, Bakhsheshi H, Lu B, Liu SCK, Oudiz RJ, Budoff MJ. Effect of ECG triggering on reproducibility of coronary artery calcium
scoring. Radiology 2001;220(3):707-11.
7. Budoff MJ and Raggi P: Coronary artery disease progression assessed by electron-beam computed tomography. Am J Cardiol
2001;88(suppl):46E-50E.
8. Shah AS, Sorochinsky B, Mao SS, Naik TK, Budoff MJ. Cardiac events and progression of coronary calcium score using electron
beam tomography. Circulation 2000;102;II-604.
9. Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a
prospective evaluation. Circulation. 2002;106(9):1077-82.
10. Qanadli SD, Mesurolle B, Aegerter P, et al. Volumetric quantification of coronary artery calcifications using dual-slice spiral CT
scanner: improved reproducibility of measurements with 180 degrees linear interpolation algorithm. J Comput Assist Tomogr
2001;25(2):278-286.

More Related Content

What's hot

Impact of statins and beta-blocker therapy on mortality after coronary artery...
Impact of statins and beta-blocker therapy on mortality after coronary artery...Impact of statins and beta-blocker therapy on mortality after coronary artery...
Impact of statins and beta-blocker therapy on mortality after coronary artery...Paul Schoenhagen
 
Iron deficiency in Heart Failure - Trial evidence
Iron deficiency in Heart Failure - Trial evidenceIron deficiency in Heart Failure - Trial evidence
Iron deficiency in Heart Failure - Trial evidencePraveen Nagula
 
American Society of Nephrology Presentation 2006
American Society of Nephrology Presentation 2006American Society of Nephrology Presentation 2006
American Society of Nephrology Presentation 2006Gary Abud Jr
 
Room a a01. mcgee-aki update on biomarkers and dx (en)
Room a a01. mcgee-aki update on biomarkers and dx (en)Room a a01. mcgee-aki update on biomarkers and dx (en)
Room a a01. mcgee-aki update on biomarkers and dx (en)SoM
 
Contrast Induced Nephropathy
Contrast Induced NephropathyContrast Induced Nephropathy
Contrast Induced NephropathyAris Tsalouchos
 
Ueda 2016 diabetes mellitus and heart failure - yahia kishk
Ueda 2016 diabetes mellitus and heart failure - yahia kishkUeda 2016 diabetes mellitus and heart failure - yahia kishk
Ueda 2016 diabetes mellitus and heart failure - yahia kishkueda2015
 
Hydration for contrast induced nephropathy
Hydration for contrast induced nephropathyHydration for contrast induced nephropathy
Hydration for contrast induced nephropathyWisit Cheungpasitporn
 
Contrast induced AKI
Contrast induced AKIContrast induced AKI
Contrast induced AKIAmit Gulati
 
Renal cell carcinoma after kidney transplantation 2017
Renal cell carcinoma after kidney transplantation 2017Renal cell carcinoma after kidney transplantation 2017
Renal cell carcinoma after kidney transplantation 2017CHAKEN MANIYAN
 
contrast nephropathy
contrast nephropathycontrast nephropathy
contrast nephropathySurendra Babu
 
Prevention is easier than solving the problem
Prevention is easier than solving the problemPrevention is easier than solving the problem
Prevention is easier than solving the problemBuddhika Illeperuma
 
Visipaque Randomized IJC 2015
Visipaque Randomized IJC 2015Visipaque Randomized IJC 2015
Visipaque Randomized IJC 2015Edwin Chu
 
Ckd mbd 2020 update prof. hussein sheashaa
Ckd mbd 2020 update prof. hussein sheashaaCkd mbd 2020 update prof. hussein sheashaa
Ckd mbd 2020 update prof. hussein sheashaaFAARRAG
 
Ace-I and Contrast induced nehropathy
Ace-I and Contrast induced nehropathyAce-I and Contrast induced nehropathy
Ace-I and Contrast induced nehropathyAhad Lodhi
 
NGAL in AKI
NGAL in AKINGAL in AKI
NGAL in AKIAla Ali
 

What's hot (18)

Impact of statins and beta-blocker therapy on mortality after coronary artery...
Impact of statins and beta-blocker therapy on mortality after coronary artery...Impact of statins and beta-blocker therapy on mortality after coronary artery...
Impact of statins and beta-blocker therapy on mortality after coronary artery...
 
Iron deficiency in Heart Failure - Trial evidence
Iron deficiency in Heart Failure - Trial evidenceIron deficiency in Heart Failure - Trial evidence
Iron deficiency in Heart Failure - Trial evidence
 
American Society of Nephrology Presentation 2006
American Society of Nephrology Presentation 2006American Society of Nephrology Presentation 2006
American Society of Nephrology Presentation 2006
 
Abcc4
Abcc4Abcc4
Abcc4
 
Room a a01. mcgee-aki update on biomarkers and dx (en)
Room a a01. mcgee-aki update on biomarkers and dx (en)Room a a01. mcgee-aki update on biomarkers and dx (en)
Room a a01. mcgee-aki update on biomarkers and dx (en)
 
Contrast Induced Nephropathy
Contrast Induced NephropathyContrast Induced Nephropathy
Contrast Induced Nephropathy
 
Ueda 2016 diabetes mellitus and heart failure - yahia kishk
Ueda 2016 diabetes mellitus and heart failure - yahia kishkUeda 2016 diabetes mellitus and heart failure - yahia kishk
Ueda 2016 diabetes mellitus and heart failure - yahia kishk
 
Hydration for contrast induced nephropathy
Hydration for contrast induced nephropathyHydration for contrast induced nephropathy
Hydration for contrast induced nephropathy
 
Contrast induced AKI
Contrast induced AKIContrast induced AKI
Contrast induced AKI
 
Abud ASN 2008-2
Abud ASN 2008-2Abud ASN 2008-2
Abud ASN 2008-2
 
Renal cell carcinoma after kidney transplantation 2017
Renal cell carcinoma after kidney transplantation 2017Renal cell carcinoma after kidney transplantation 2017
Renal cell carcinoma after kidney transplantation 2017
 
contrast nephropathy
contrast nephropathycontrast nephropathy
contrast nephropathy
 
Ojchd.000533
Ojchd.000533Ojchd.000533
Ojchd.000533
 
Prevention is easier than solving the problem
Prevention is easier than solving the problemPrevention is easier than solving the problem
Prevention is easier than solving the problem
 
Visipaque Randomized IJC 2015
Visipaque Randomized IJC 2015Visipaque Randomized IJC 2015
Visipaque Randomized IJC 2015
 
Ckd mbd 2020 update prof. hussein sheashaa
Ckd mbd 2020 update prof. hussein sheashaaCkd mbd 2020 update prof. hussein sheashaa
Ckd mbd 2020 update prof. hussein sheashaa
 
Ace-I and Contrast induced nehropathy
Ace-I and Contrast induced nehropathyAce-I and Contrast induced nehropathy
Ace-I and Contrast induced nehropathy
 
NGAL in AKI
NGAL in AKINGAL in AKI
NGAL in AKI
 

Viewers also liked

Viewers also liked (19)

125 ct based characterization
125 ct based characterization125 ct based characterization
125 ct based characterization
 
Final clickable pps for vp s ymposium aha 2001
Final clickable pps for vp s ymposium aha 2001Final clickable pps for vp s ymposium aha 2001
Final clickable pps for vp s ymposium aha 2001
 
Kwong
KwongKwong
Kwong
 
Arterial remodeling in st vs. unst coronary synd schoenhagen1
Arterial remodeling in st vs. unst coronary synd  schoenhagen1Arterial remodeling in st vs. unst coronary synd  schoenhagen1
Arterial remodeling in st vs. unst coronary synd schoenhagen1
 
Adventitial fat presentation
Adventitial fat presentationAdventitial fat presentation
Adventitial fat presentation
 
Esv3n11
Esv3n11Esv3n11
Esv3n11
 
Figuresforpaper 3
Figuresforpaper 3Figuresforpaper 3
Figuresforpaper 3
 
Es v2n19
Es v2n19Es v2n19
Es v2n19
 
Herrera
HerreraHerrera
Herrera
 
Esv2n26
Esv2n26Esv2n26
Esv2n26
 
Esv3n3
Esv3n3Esv3n3
Esv3n3
 
168 catheter based detection of vulnerable plaque
168 catheter based detection of vulnerable plaque168 catheter based detection of vulnerable plaque
168 catheter based detection of vulnerable plaque
 
233 cd40
233 cd40233 cd40
233 cd40
 
Esv2n39
Esv2n39Esv2n39
Esv2n39
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Falk
FalkFalk
Falk
 
Esv2n32
Esv2n32Esv2n32
Esv2n32
 
Esv2n49
Esv2n49Esv2n49
Esv2n49
 
Everybody has atherosclerosis
Everybody has atherosclerosisEverybody has atherosclerosis
Everybody has atherosclerosis
 

Similar to Esv2n36

220 statin therapy and coronary calcification
220 statin therapy and coronary calcification220 statin therapy and coronary calcification
220 statin therapy and coronary calcificationSHAPE Society
 
Septic cardiomyopathy colour
Septic cardiomyopathy   colourSeptic cardiomyopathy   colour
Septic cardiomyopathy colourPalepu BN Gopal
 
Proteinuria as Cardiovascular Risk Factor
Proteinuria as Cardiovascular Risk FactorProteinuria as Cardiovascular Risk Factor
Proteinuria as Cardiovascular Risk FactorJAFAR ALSAID
 
Anginal pectoris refractory to standard medical therapy i
Anginal pectoris refractory to standard medical therapy iAnginal pectoris refractory to standard medical therapy i
Anginal pectoris refractory to standard medical therapy iBALASUBRAMANIAM IYER
 
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdfKs doctor
 
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptxHF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptxJEEWANKUMAR14
 
Arterial and valvular disorders
Arterial and valvular disordersArterial and valvular disorders
Arterial and valvular disordersAdrian Covic
 
Protecting vascular events in NVAF
Protecting vascular events in NVAFProtecting vascular events in NVAF
Protecting vascular events in NVAF우석 이
 
Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?My Healthy Waist
 
Acute Decompensated Heart Failure
Acute Decompensated Heart FailureAcute Decompensated Heart Failure
Acute Decompensated Heart Failuredrucsamal
 
Acute Decompensated Heart Failure CSI13
Acute Decompensated Heart Failure CSI13Acute Decompensated Heart Failure CSI13
Acute Decompensated Heart Failure CSI13drucsamal
 
Transfusion trigger in Intensive Care Unit
Transfusion trigger in Intensive Care UnitTransfusion trigger in Intensive Care Unit
Transfusion trigger in Intensive Care UnitYazan Kherallah
 
Non Invasive testing of myocardial ischemia AA.pptx
Non Invasive testing of myocardial ischemia AA.pptxNon Invasive testing of myocardial ischemia AA.pptx
Non Invasive testing of myocardial ischemia AA.pptxhospital
 

Similar to Esv2n36 (20)

220 statin therapy and coronary calcification
220 statin therapy and coronary calcification220 statin therapy and coronary calcification
220 statin therapy and coronary calcification
 
220 statin therapy and coronary calcification
220 statin therapy and coronary calcification220 statin therapy and coronary calcification
220 statin therapy and coronary calcification
 
Supra Rx Dose of ARBs
Supra Rx Dose of ARBsSupra Rx Dose of ARBs
Supra Rx Dose of ARBs
 
Septic cardiomyopathy colour
Septic cardiomyopathy   colourSeptic cardiomyopathy   colour
Septic cardiomyopathy colour
 
Proteinuria as Cardiovascular Risk Factor
Proteinuria as Cardiovascular Risk FactorProteinuria as Cardiovascular Risk Factor
Proteinuria as Cardiovascular Risk Factor
 
Anginal pectoris refractory to standard medical therapy i
Anginal pectoris refractory to standard medical therapy iAnginal pectoris refractory to standard medical therapy i
Anginal pectoris refractory to standard medical therapy i
 
Pragmatic Use of Rosuvastatin for CVD Prevention
Pragmatic Use of Rosuvastatin for CVD PreventionPragmatic Use of Rosuvastatin for CVD Prevention
Pragmatic Use of Rosuvastatin for CVD Prevention
 
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
1110414-降低糖尿病患者罹患心腎疾病的風險跟血糖達標一樣重要.pdf
 
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptxHF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
 
CKD-MBD:Messages from clinical trials
CKD-MBD:Messages from clinical trialsCKD-MBD:Messages from clinical trials
CKD-MBD:Messages from clinical trials
 
Dr.Syed Imran
Dr.Syed ImranDr.Syed Imran
Dr.Syed Imran
 
Arterial and valvular disorders
Arterial and valvular disordersArterial and valvular disorders
Arterial and valvular disorders
 
Protecting vascular events in NVAF
Protecting vascular events in NVAFProtecting vascular events in NVAF
Protecting vascular events in NVAF
 
Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?
 
Acute Decompensated Heart Failure
Acute Decompensated Heart FailureAcute Decompensated Heart Failure
Acute Decompensated Heart Failure
 
Acute Decompensated Heart Failure CSI13
Acute Decompensated Heart Failure CSI13Acute Decompensated Heart Failure CSI13
Acute Decompensated Heart Failure CSI13
 
Aki cticu final
Aki cticu finalAki cticu final
Aki cticu final
 
Acute Kidney Injury in the Cardiac Surgery Patient
Acute Kidney Injury in the Cardiac Surgery PatientAcute Kidney Injury in the Cardiac Surgery Patient
Acute Kidney Injury in the Cardiac Surgery Patient
 
Transfusion trigger in Intensive Care Unit
Transfusion trigger in Intensive Care UnitTransfusion trigger in Intensive Care Unit
Transfusion trigger in Intensive Care Unit
 
Non Invasive testing of myocardial ischemia AA.pptx
Non Invasive testing of myocardial ischemia AA.pptxNon Invasive testing of myocardial ischemia AA.pptx
Non Invasive testing of myocardial ischemia AA.pptx
 

More from Society for Heart Attack Prevention and Eradication

More from Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 

Recently uploaded

Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHUKanhu Charan
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxSizan Thapa
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptxPulkitMittal54
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...Genesis Institute of Pharmacy, Radhanagari.
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhanthesalberry
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKQuick MedTalk
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdfHongBiThi1
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 

Recently uploaded (20)

Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptx
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhan
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 

Esv2n36

  • 1. Editorial Slides VP Watch – September 11, 2002 - Volume 2, Issue 36 Influence of Statin Therapy on Progression ofInfluence of Statin Therapy on Progression of Coronary CalcificationCoronary Calcification Matthew J. Budoff, MD, FACCMatthew J. Budoff, MD, FACC Assistant Professor of MedicineAssistant Professor of Medicine Division of CardiologyDivision of Cardiology Harbor- UCLA Medical Center Torrance, CA, USA
  • 2. Coronary Calcification Coronary Calcification has been demonstrated to be a marker of atherosclerosis and cardiovascular risk1 Electron Beam Tomography (EBT) is a non- invasive method to detect and quantify coronary calcification Prognostic studies have demonstrated an increased risk of future cardiac events with increased coronary calcium scores1
  • 3. Progression of AtherosclerosisProgression of Atherosclerosis Regression studies have predominantly been performed with angiographic trials, requiring multiple invasive angiographic studies These studies are typically 2-4 years in duration, demonstrating small but significant changes, with luminal diameter changing by microns It is well known that Luminal stenosis by angiography poorly quantitates atherosclerotic burden
  • 4. EBT and ProgressionEBT and Progression Several studies with EBT have demonstrated progression of calcium scores of up to 50% per year2,3,4 Variability of sequential EBT scans has been demonstrated to range from 8-24% (mean), with median values of 5-8%5,6 It has been demonstrated that EBT can track progression of coronary calcium over time, and progression of CAC has been demonstrated to be associated with increased cardiovascular risk7,8
  • 5. Progression of CAC and The Relation to Therapy (adapted from ref 7) AUTHOR n KNOWN CAD? No Therapy Statin Treatment Type of Therapy Janowitz 20 No Yes 18% 27% -------- --------- Callister 27 No 44% -------- --------- Callister 149 No 52% (n = 44) 5% (n = 105) Statins Maher 81 No 24% -------- --------- Budoff 299 No 36% (n = 239) 15% (n = 60) Statins Mitchell 347 No 21% --------- ---------- Brown 160 Yes 40% 20% Simvastatin, Niacin Achenbach 66 No 25% 8.8% Cerivastatin 0.3 mg/day
  • 6. Annual Event Rate with Progression of CAC (Adapted from Reference 8) 0 1.5 6.45 0 1 2 3 4 5 6 7 AnnualEventRates No progression 1-20% Increase >20% Increase Annual CAC Score Change Shah et al, AHA 2001
  • 7. Calcium Score progression with increasing LDL Cholesterol (Adapted from Reference 2) +120% 0 –80% 60 120 200 LDL (mg/dL) Treated Untreated Suboptimal Therapy (LDL >120 mg/dl) Callister et al. N Engl J Med. 1998;339:1972-1978. CACScoreChange
  • 8. Achenbach et al, Circulation 2002 66 patients with known high cholesterol underwent EBT scanning Baseline calcium scores were 155 mm3 Patients were observed for a mean of 14 months Follow-up scan revealed score increase to 201 mm3 (25%)
  • 9. Treatment Arm - Cholesterol Patients were then treated (open label) on Cerivastatin 0.3 mg/dl for 12 months Mean LDL was reduced from was 164 mg/dl to 107 mg/dl (35% reduction, p<0.0001) Mean HDL increased from 51 mg/dl to 52 mg/dl (1.7% increased, not significant) Mean Triglycerides decreased from 184 mg/dl to 152 mg/dl (17%, p=0.004)
  • 10. EBT Changes with Statin Therapy EBT score increased from 201 mm3 to 203 mm3 Median increase in score (on treatment was 8.8%, significantly lower than no therapy 25%, p<0.0001) In 32 patients, on-treatment LDL cholesterol was <100 mg/dl, median change was –3.4%
  • 11. Progression of EBT by LDL -3.4 8.8 25 -100102030 Annual Progression <100 Treated Untreated TREATMENT LDL Achenbach, Circulation 2002 P<0.001
  • 12. Study Limitations Study was stopped prematurely due to Cerivastatin’s withdrawal from the marketplace Open Label study 80% triggering of EBT used (higher variability than early diastolic trigger)
  • 13. Conclusions: Cerivastatin significantly reduced rates of coronary calcium progression Achieving an LDL cholesterol of <100 mg/dl was associated with a median decrease of the coronary calcium burden (-3.4%) This study correlates with retrospective studies previously published on EBT that statin therapy will slow calcification deposition
  • 14. Questions: Does slowing of the calcification burden correlate with slowing of the atherosclerotic plaque volume ? Will helical (fast) CT be able to measure these changes, given the lower reproducibility due to slower scan times?10 Will slowing of the coronary calcium burden be associated with a reduction in cardiovascular events?
  • 15. References 1. Budoff MJ. Prognostic Value of Coronary Artery Calcification. J Clin Out Manag 2001:8;42-48. 2. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo NJ. Effect of HMG-CoA Reductase Inhibitors on Coronary Artery Disease as Assessed by Electron-Beam Computed Tomography. N Engl J Med 1998;339:1972-8. 3. Maher JE, Bielak LF, Raz JA, Sheedy PF, Schwartz RS, Peyser PA. Progression of coronary artery calcification: A pilot study. Mayo Clin Proc 1999;74:347-355. 4. Budoff MJ, Lane KL, Bakhsheshi H, et al. Rates of progression of coronary calcification by electron beam computed tomography. Am J Cardiol 2000; 86:8-11. 5. Achenbach S, Ropers D, Mohlenkamp S, et al. Variability of Repeated Coronary Artery Calcium Measurements by Electron Beam Tomography. Am J Cardiol 2001;87:210-213. 6. Mao SS, Bakhsheshi H, Lu B, Liu SCK, Oudiz RJ, Budoff MJ. Effect of ECG triggering on reproducibility of coronary artery calcium scoring. Radiology 2001;220(3):707-11. 7. Budoff MJ and Raggi P: Coronary artery disease progression assessed by electron-beam computed tomography. Am J Cardiol 2001;88(suppl):46E-50E. 8. Shah AS, Sorochinsky B, Mao SS, Naik TK, Budoff MJ. Cardiac events and progression of coronary calcium score using electron beam tomography. Circulation 2000;102;II-604. 9. Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation. 2002;106(9):1077-82. 10. Qanadli SD, Mesurolle B, Aegerter P, et al. Volumetric quantification of coronary artery calcifications using dual-slice spiral CT scanner: improved reproducibility of measurements with 180 degrees linear interpolation algorithm. J Comput Assist Tomogr 2001;25(2):278-286.

Editor's Notes

  1. &amp;lt;number&amp;gt;
  2. &amp;lt;number&amp;gt; Using the volumetric calcium scoring method, it is possible to explore the potential for regression of atherosclerotic plaque volume with primary or secondary CHD prevention. In a retrospective study, Callister et al tested the hypothesis that treatment with HMG-CoA reductase inhibitors (statins) would result in a change in coronary plaque volume as measured by EBT. One hundred and forty-nine patients with no history of CHD who had been referred for EBT screening were evaluated. All patients underwent a baseline EBT scan and then returned for a follow-up scan 1 year later. After their initial screening, 70% of the patients had received lipid-lowering treatment with a statin and 30% had not. Patients were classified into 3 groups; Group 1 – no statin therapy; Group 2 – statin therapy and follow-up average LDL-C levels &amp;gt;120 mg/dL; Group 3 – statin therapy and follow-up average LDL-C &amp;lt;120 mg/dL. Callister TQ, Raggi P, Cooil B, et al. N Engl J Med. 1998;339:1972-1978.